Lamotrigine Tablet
Product Images NDC 70518-2577

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Lamotrigine (NDC 70518-2577). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

2d955155 686d 40cd 898e Df7d760247a5 789 2

Lamotrigine tablets in various strengths and shapes from RemedyRepack Inc. Visible are 25 mg white oval tablets embossed with 'U' and '111'; 100 mg white triangular tablets embossed with 'U' and '112'; 150 mg white triangular tablets embossed with 'U' and '113'; and 200 mg light blue triangular tablets embossed with 'U' and '114'.*

FDA Label Image

Remedy_label (Remedy Label)

Lamotrigine 150 mg oral tablet label repackaged by RemedyRepack Inc. The label shows the proprietary name 'lamoTRIgine,' strength 150 mg, tablet dosage form, and a quantity of 30. Manufacturer is Unichem Labs Ltd., Goa, India. Includes a QR code and storage instructions to keep at 20-25°C (68-77°F). Repackaged by RemedyRepack Inc., Indiana, PA.*

FDA Label Image

Ad7af627 Ea4b 4a78 A71e Db1255416d1e 01

Chemical structure diagram of lamotrigine, showing its molecular arrangement including chlorine atoms and nitrogen-containing rings.*

FDA Label Image

Ad7af627 Ea4b 4a78 A71e Db1255416d1e 02

A Kaplan-Meier survival curve showing failure probability over weeks for Lamotrigine and placebo groups. The x-axis represents weeks from 0 to 100, and the y-axis represents failure probability percentage from 0 to 100%. Two curves are shown: one labeled Lamotrigine and the other Placebo, with censored data points marked by crosses.*

FDA Label Image

Ad7af627 Ea4b 4a78 A71e Db1255416d1e 03

A survival analysis Kaplan-Meier curve plotting failure probability (%) against weeks, comparing Lamotrigine and placebo groups. The graph shows two step functions with censored data points marked. The placebo group demonstrates a higher failure probability over time compared to the Lamotrigine group up to approximately 75 weeks.*

FDA Label Image

Mm2 (Lamotrigine 150mg 70518 2577 01)

Lamotrigine 150 mg oral tablet packaging label, repackaged by RemedyRepack Inc. The label shows one tablet quantity, with source manufacturing by Unichem Labs Ltd., Goa, India. Includes storage instructions (20-25°C, excursions permitted 15-30°C) and a QR code. The label also includes the NDC 70518-2577-01 and warnings to keep medication out of children's reach.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.